Ajooni Biotech Ltd

On 04-Dec, Ajooni Biotech Ltd’s stock price fell by 2.98% to ₹4.56, continuing a downward trend that has persisted over the past year. Despite the company reporting consistent profit growth, the shares have underperformed significantly against benchmark indices and sector peers, reflecting investor concerns over its long-term financial health and market positioning.

Ajooni Biotech has shown significant growth in net sales and profit, with net sales increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, and profit after tax rising from 0.41 crore to 3.37 crore. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash management.

As of 19-Nov, Ajooni Biotech Ltd's stock price is Rs. 4.67, down 5.47%, and has reached a 52-week low of Rs. 4.16. The stock is underperforming significantly compared to the Sensex, with a year-to-date decline of 39.90% and decreasing investor participation.

Ajooni Biotech has shown significant growth in net sales and profitability, with net sales increasing from 39.72 Cr in Mar'19 to 114.69 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 3.37 Cr in the same period. However, the company faces challenges in cash flow management, experiencing a net cash outflow of 10.00 Cr in Mar'25.

Ajooni Biotech has shown significant growth in net sales and profitability from March 2021 to March 2025, with net sales increasing from 51.04 crore to 114.69 crore and profit after tax rising from 0.37 crore to 3.37 crore, despite experiencing negative cash flow in March 2025. Total assets and liabilities have also expanded substantially during this period.

Ajooni Biotech has shown significant growth in net sales and profitability, with net sales increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, and profit after tax rising from 0.41 crore to 3.37 crore during the same period. However, the company faced negative cash flow from operating activities of -17.00 crore in March 2025.

Ajooni Biotech has shown significant growth in net sales, increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, with profit after tax rising from 0.41 crore to 3.37 crore during the same period, despite fluctuations in cash flow. Total assets and liabilities also grew substantially, reflecting the company's overall financial expansion.

Ajooni Biotech has shown significant growth in net sales and profitability from 2021 to 2025, with net sales increasing from 51.04 Cr to 114.69 Cr and profit after tax rising from 0.35 Cr to 3.37 Cr. However, cash flow from operating activities turned negative in 2025, contrasting with a positive cash flow in 2024.

As of 12-Sep, Ajooni Biotech Ltd's stock price is Rs 5.15, down 0.19%, and has significantly underperformed the market, with a 50.19% decline over the past year. Despite positive quarterly results, the stock's weak fundamentals and poor performance compared to the Sensex highlight ongoing challenges in attracting investor confidence.

As of 11-Sep, Ajooni Biotech Ltd's stock price is Rs 5.16, showing a slight increase but a significant decline of 50.10% over the past year. Despite positive quarterly results and increased investor participation, the stock's long-term fundamentals are weak, leading to cautious investor sentiment.

As of 10-Sep, Ajooni Biotech Ltd's stock price is Rs 5.15, down 1.34%, and has significantly underperformed with a 50.19% decline over the past year. Despite positive quarterly results, weak fundamentals and negative market sentiment contribute to its bearish trend.

Ajooni Biotech has shown significant growth in net sales and profitability, with net sales increasing from 39.72 Cr in Mar'19 to 114.69 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 3.37 Cr. However, cash flow from operating activities was negative at -17.00 Cr in Mar'25, indicating a challenge in cash flow management.

As of 09-Sep, Ajooni Biotech Ltd's stock price is Rs 5.22, with no change and significant underperformance in the short term. Despite positive quarterly results, the stock's long-term fundamentals are weak, contributing to its stagnation and negative investor sentiment.

As of 08-Sep, Ajooni Biotech Ltd is priced at Rs 5.22, showing a slight increase but trading below its moving averages and close to its 52-week low. Despite positive quarterly results, the stock has underperformed significantly compared to the Sensex and faces challenges in regaining investor confidence.

As of 05-Sep, Ajooni Biotech Ltd's stock price is Rs 5.21, down 0.57%, and has significantly underperformed its sector and the Sensex. Despite recent positive earnings, the stock's long-term fundamentals are weak, leading to a substantial decline in both short-term and year-to-date performance.

As of 04-Sep, Ajooni Biotech Ltd's stock price is Rs 5.24, showing a slight increase but underperforming with a one-week return of -2.78% and a year-to-date return of -32.56%. Despite strong recent financial results, the stock's bearish trend and weak long-term fundamentals contribute to a negative outlook.

As of 03-Sep, Ajooni Biotech Ltd's stock price is Rs 5.19, down 1.14%, and trading below all key moving averages, indicating a bearish trend. Despite recent positive quarterly results, weak long-term fundamentals and significant underperformance compared to the sector have led to a decline in its market value.

As of 02-Sep, Ajooni Biotech Ltd's stock price is Rs 5.25, down 1.13%, and close to its 52-week low. Despite recent positive quarterly results, the stock has declined 44.09% over the past year, indicating weak long-term performance and declining investor interest.